Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The Juilliard-trained talent said he's honored to get the gig: "Our queer siblings across the country who are being unfairly ...

Seattle's Nautilus Biotechnology is laying off 16% of workforce, and plans to release its commercial platform in late 2026.

David Furnish’s leadership at EJAF proves brands can do more than raise awareness —they can dismantle stigma and drive ...

Salesforce is expected to report fourth-quarter results after the market closes Wednesday, with analysts largely bullish on ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

A common CV risk factor calculator for patients with HIV underestimates risk for Black patients and women, while risk for ...

Innovation in HIV care and prevention is transforming the fight, but there is more to be done in order to meet the UNAIDS targets of ending the HIV epidemic by 2030 ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

A new collaboration in the US between the Patient Advocate Foundation's (PAF) Patient Insight Institute, Gilead Sciences and ...